Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective

被引:0
作者
Jinsui Zhang
Zemin Xia
Wanjie Guo
Xiaoxiao Ren
Fang Liu
Gargi Ratnaparkhi
Amit Pagada
Subhashini Subramanian
Min Hu
Wen Chen
机构
[1] Fudan University,School of Public Health
[2] Beijing Novartis Pharma Co.,undefined
[3] Ltd.,undefined
[4] Novartis Healthcare Pvt. Ltd.,undefined
来源
Dermatology and Therapy | 2023年 / 13卷
关键词
Cost-effectiveness; Psoriasis; Secukinumab; Biologics; Incremental cost-effectiveness ratio; Quality-adjusted life year; China;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2681 / 2696
页数:15
相关论文
共 126 条
[1]  
Boehncke WH(2015)Psoriasis Lancet 386 983-994
[2]  
Schon MP(2021)The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study Front Med (Lausanne) 8 743180-667
[3]  
Damiani G(2012)Prevalence of psoriasis in China: a population-based study in six cities Eur J Dermatol 22 663-46389
[4]  
Bragazzi NL(2017)Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients Oncotarget 8 46381-47
[5]  
Karimkhani Aksut C(2014)Epidemiology and treatment of psoriasis: a Chinese perspective Psoriasis (Auckl) 4 37-26
[6]  
Ding X(2022)Epidemiology of psoriasis and comorbid diseases: a narrative review Front Immunol 13 880201-795
[7]  
Wang T(2020)Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities Front Pharmacol 11 117-26
[8]  
Shen Y(2016)A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis J Dermatolog Treat 27 19-710
[9]  
Chen K(2021)Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study Health Qual Life Outcomes 19 271-1047
[10]  
Wang G(2019)Disease burden and quality of life in patients with psoriasis: an internet-based questionnaire Chin J Dermatol 52 791-990